Latanoprostene bunod is a novel compound containing a PG analogue and Nitric Oxide. It appears to offer about 1mmHg further lowering of IOP versus latanoprost, and is a well tolerated medication in early studies; data has been presented at ARVO in 2013. Nitrous oxide has been shown to relax the ciliary muscle and trabecular meshwork, possibly therefore having a combined method of action with enhanced trabecular outflow, and also increased uveoscleral outflow.

Therefore, at this stage, this new medication is likely judged to offer a small but significant advance in treatment, and its release hopefully in the next year or two is anticipated with optimism.